MeSH D016030 - kidney transplantation
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Bristol Myers Squibb | Belatacept | Nulojix |  | 2011-06-17 | $26 M | Y2013 |
| Hansa Biopharma | Imlifidase | Idefirix |  | 2020-08-25 |  |  |
| Novartis | Basiliximab | Simulect |  | 1998-10-09 |  |  |
| Pfizer | Sirolimus | Rapamune |  | 2001-03-13 | $170 M | Y2016 |
| Roche | Daclizumab | Zenapax |  | 1999-02-26 |  |  |
| Teva | Tacrolimus | Tacforius |  | 2017-12-08 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
100%42/42
Phase 2
45%34/76
Phase 3
62%29/47
Approved: 5Overall Success rate: 28%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use